E. Alberto

发表

The Effectiveness and Safety of 1% Silver Sulfadiazine (Flammazine)Cream in Preventing Infection in Potentially Contaminated TraumaticWounds among Pediatric Patients 2 To <18 Years Old: An Open-Label,Single-Arm Phase 3 Clinical Trial

J. Guerrero, M. R. Capeding, Edison R Alberto, 2017 .

Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9–12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial

K. Neuzil, Yuxiao Tang, A. Marfin, 2020, Vaccine: X.

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

F. Rockhold, Ping Li, G. Siber, 2022, The Lancet.

Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study

Jerome H. Kim, J. Yang, J. Lynch, 2020, EClinicalMedicine.

A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age

Min Soo Kim, Jerome H. Kim, J. Yang, 2022, The Lancet regional health. Western Pacific.

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

J. Yang, J. Y. Park, B. T. Tadesse, 2022, npj Vaccines.

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

Jerome H. Kim, J. Yang, J. Y. Park, 2022, NPJ vaccines.

Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report

Jerome H. Kim, J. Yang, J. Lynch, 2020, Vaccine.

Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.

Z. Bhutta, S. Juvekar, E. Marchetti, 2014, The Lancet. Infectious diseases.

Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority study.

A. Versteilen, M. R. Capeding, P. Bagchi, 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority study.

M. R. Capeding, A. Macura-Biegun, M. Rauscher, 2014, Vaccine.

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents

I. Smolenov, P. López, L. Bravo, 2023, medRxiv.

Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study

Haijing Qin, Ping Li, G. Siber, 2023, Vaccine.

The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of Immunogenicity

S. Gatchalian, I. Dieussaert, L. Szenborn, 2009, The Pediatric infectious disease journal.

Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV–Primed Children in the Philippines

M. R. Capeding, T. Laot, A. Bouckenooghe, 2018, The Journal of infectious diseases.

SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF THE 10-VALENT PNEUMOCOCCAL NONTYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE COADMINISTERED WITH DTPW-HBV/HIB AND POLIOVIRUS VACCINES

S. Gatchalian, I. Dieussaert, L. Szenborn, 2011, The Pediatric infectious disease journal.